GB0109146D0 - Treatment of type 2 diabetes - Google Patents

Treatment of type 2 diabetes

Info

Publication number
GB0109146D0
GB0109146D0 GBGB0109146.1A GB0109146A GB0109146D0 GB 0109146 D0 GB0109146 D0 GB 0109146D0 GB 0109146 A GB0109146 A GB 0109146A GB 0109146 D0 GB0109146 D0 GB 0109146D0
Authority
GB
United Kingdom
Prior art keywords
diabetes
type
treatment
individual
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0109146.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Priority to GBGB0109146.1A priority Critical patent/GB0109146D0/en
Publication of GB0109146D0 publication Critical patent/GB0109146D0/en
Priority to AU2002244860A priority patent/AU2002244860B2/en
Priority to JP2002580913A priority patent/JP2004525179A/ja
Priority to CZ20032927A priority patent/CZ20032927A3/cs
Priority to NZ528172A priority patent/NZ528172A/en
Priority to CNB028080955A priority patent/CN1248683C/zh
Priority to HU0303876A priority patent/HUP0303876A3/hu
Priority to MXPA03009224A priority patent/MXPA03009224A/es
Priority to IL15782102A priority patent/IL157821A0/xx
Priority to PL02366633A priority patent/PL366633A1/xx
Priority to RU2003132687/14A priority patent/RU2328283C2/ru
Priority to HK04101781.7A priority patent/HK1059213B/en
Priority to EP02713070A priority patent/EP1377278B1/en
Priority to DE60215787T priority patent/DE60215787T2/de
Priority to PCT/GB2002/001674 priority patent/WO2002083109A1/en
Priority to CA002443229A priority patent/CA2443229A1/en
Priority to KR10-2003-7013350A priority patent/KR20040025915A/ko
Priority to US10/474,676 priority patent/US20040209891A1/en
Priority to AT02713070T priority patent/ATE344029T1/de
Priority to UA2003109184A priority patent/UA76452C2/uk
Priority to ZA200307156A priority patent/ZA200307156B/en
Priority to NO20034549A priority patent/NO20034549D0/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
GBGB0109146.1A 2001-04-11 2001-04-11 Treatment of type 2 diabetes Ceased GB0109146D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB0109146.1A GB0109146D0 (en) 2001-04-11 2001-04-11 Treatment of type 2 diabetes
AT02713070T ATE344029T1 (de) 2001-04-11 2002-04-10 Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern
RU2003132687/14A RU2328283C2 (ru) 2001-04-11 2002-04-10 Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
EP02713070A EP1377278B1 (en) 2001-04-11 2002-04-10 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
CZ20032927A CZ20032927A3 (cs) 2001-04-11 2002-04-10 Léčení cukrovky typu 2 inhibitory z dipeptidylpeptidázy IV
NZ528172A NZ528172A (en) 2001-04-11 2002-04-10 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
CNB028080955A CN1248683C (zh) 2001-04-11 2002-04-10 二肽基肽酶iv抑制剂在制备治疗2型糖尿病的药物中的用途
HU0303876A HUP0303876A3 (en) 2001-04-11 2002-04-10 Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv
MXPA03009224A MXPA03009224A (es) 2001-04-11 2002-04-10 Tratamiento de diabetes tipo 2 con inhibidores de peptidasa de dipeptidilo iv.
IL15782102A IL157821A0 (en) 2001-04-11 2002-04-10 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
PL02366633A PL366633A1 (en) 2001-04-11 2002-04-10 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
AU2002244860A AU2002244860B2 (en) 2001-04-11 2002-04-10 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
HK04101781.7A HK1059213B (en) 2001-04-11 2002-04-10 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
JP2002580913A JP2004525179A (ja) 2001-04-11 2002-04-10 ジペプチジルペプチダーゼｉｖ阻害剤でのｉｉ型糖尿病の処置
DE60215787T DE60215787T2 (de) 2001-04-11 2002-04-10 Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
PCT/GB2002/001674 WO2002083109A1 (en) 2001-04-11 2002-04-10 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
CA002443229A CA2443229A1 (en) 2001-04-11 2002-04-10 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
KR10-2003-7013350A KR20040025915A (ko) 2001-04-11 2002-04-10 디펩티딜 펩티다아제 ｉｖ의 저해제를 이용한 2형당뇨병의 치료
US10/474,676 US20040209891A1 (en) 2001-04-11 2002-04-10 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
UA2003109184A UA76452C2 (en) 2001-04-11 2002-10-04 Use of inhibitor of dipeptidyl peptidase iv for treating early stages of diabetes type 2
ZA200307156A ZA200307156B (en) 2001-04-11 2003-09-12 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV.
NO20034549A NO20034549D0 (no) 2001-04-11 2003-10-09 Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0109146.1A GB0109146D0 (en) 2001-04-11 2001-04-11 Treatment of type 2 diabetes

Publications (1)

Publication Number Publication Date
GB0109146D0 true GB0109146D0 (en) 2001-05-30

Family

ID=9912727

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0109146.1A Ceased GB0109146D0 (en) 2001-04-11 2001-04-11 Treatment of type 2 diabetes

Country Status (21)

Country Link
US (1) US20040209891A1 (enExample)
EP (1) EP1377278B1 (enExample)
JP (1) JP2004525179A (enExample)
KR (1) KR20040025915A (enExample)
CN (1) CN1248683C (enExample)
AT (1) ATE344029T1 (enExample)
AU (1) AU2002244860B2 (enExample)
CA (1) CA2443229A1 (enExample)
CZ (1) CZ20032927A3 (enExample)
DE (1) DE60215787T2 (enExample)
GB (1) GB0109146D0 (enExample)
HU (1) HUP0303876A3 (enExample)
IL (1) IL157821A0 (enExample)
MX (1) MXPA03009224A (enExample)
NO (1) NO20034549D0 (enExample)
NZ (1) NZ528172A (enExample)
PL (1) PL366633A1 (enExample)
RU (1) RU2328283C2 (enExample)
UA (1) UA76452C2 (enExample)
WO (1) WO2002083109A1 (enExample)
ZA (1) ZA200307156B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60222667T2 (de) 2001-06-27 2008-07-17 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
GB0125445D0 (en) * 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
AU2002952946A0 (en) * 2002-11-27 2002-12-12 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06001601A (es) 2003-08-13 2006-08-25 Takeda Pharmaceutical Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20070149451A1 (en) * 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
KR20120008093A (ko) 2003-11-17 2012-01-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
ES2684325T5 (es) 2004-01-20 2024-06-10 Novartis Ag Formulación y proceso de compresión directa
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
AU2005267093B2 (en) * 2004-07-23 2009-10-01 Nuada Llc Peptidase inhibitors
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
KR20080000665A (ko) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 디펩티딜 펩티다아제-ⅳ 억제제
MX2008001799A (es) * 2005-08-11 2008-04-16 Hoffmann La Roche Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
SI1942898T2 (sl) 2005-09-14 2014-08-29 Takeda Pharmaceutical Company Limited Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
FR2938999B1 (fr) * 2008-11-24 2011-07-01 Oreal Procede de preparation d'un parfum au sein d'un systeme comportant une pluralite de terminaux interactifs de formulation de parfums et un serveur agence pour echanger des donnees avec la pluralite de terminaux
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
ES2353728T3 (es) * 1999-02-10 2011-03-04 Curis, Inc. Péptido yy (pyy) para tratar trastornos metabólicos de la glucosa.
GB9906714D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en) * 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2001034594A1 (en) * 1999-11-12 2001-05-17 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
DK1283735T4 (da) * 2000-03-31 2013-02-04 Royalty Pharma Collection Trust Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment

Also Published As

Publication number Publication date
RU2003132687A (ru) 2005-04-10
NO20034549L (no) 2003-10-09
ATE344029T1 (de) 2006-11-15
CN1501796A (zh) 2004-06-02
CZ20032927A3 (cs) 2004-06-16
NO20034549D0 (no) 2003-10-09
CN1248683C (zh) 2006-04-05
WO2002083109A1 (en) 2002-10-24
PL366633A1 (en) 2005-02-07
MXPA03009224A (es) 2004-01-29
HUP0303876A2 (hu) 2004-03-01
UA76452C2 (en) 2006-08-15
JP2004525179A (ja) 2004-08-19
ZA200307156B (en) 2004-06-04
NZ528172A (en) 2004-09-24
US20040209891A1 (en) 2004-10-21
DE60215787T2 (de) 2007-08-30
DE60215787D1 (de) 2006-12-14
EP1377278B1 (en) 2006-11-02
IL157821A0 (en) 2004-03-28
CA2443229A1 (en) 2002-10-24
KR20040025915A (ko) 2004-03-26
AU2002244860B2 (en) 2006-11-16
HUP0303876A3 (en) 2005-06-28
RU2328283C2 (ru) 2008-07-10
HK1059213A1 (en) 2004-06-25
EP1377278A1 (en) 2004-01-07

Similar Documents

Publication Publication Date Title
GB0109146D0 (en) Treatment of type 2 diabetes
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
EP1505990A4 (en) METHOD FOR THE TREATMENT OF HEPATITIS
MY151032A (en) Treatment of tnf? related disorders
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
GB0130677D0 (en) Medicaments and novel compounds
PL371205A1 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
WO2004110392A3 (en) Compositions and methods for treating coronavirus infection and sars
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
GB0020504D0 (en) Therapeutic method
WO2004030631A3 (en) Anti-cancer and anti-infectious disease compositions and methods for using same
PL1603584T3 (pl) Aplidyna do leczenia szpiczaka mnogiego
FR2839450B1 (fr) Preparation medicamenteuse notamment pour le traitement des hernies discales
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
PL374696A1 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
MX2007004040A (es) Uso para alfa-simpatomimeticos con estructura de 2-imidazolina.
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
UA35854A (uk) Спосіб лікування приховано протікаючого силікотуберкульозу
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)